InnerPulse(TM) Secures $50 Million in New Equity Financing

    RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire/ -- InnerPulse, Inc,
 a privately held company developing unique technologies for the treatment
 of abnormal heart rhythms, announced today the closing of $50 million in
 new equity financing. The new capital will be used for the completion of
 the Company's novel implantable defibrillator and to support the
 infrastructure required to advance the Company from its early developmental
 phase to human clinical trials and commercialization.
     The syndicate of investors included Johnson & Johnson Development
 Corporation, Medtronic, Inc., Synergy Life Science Partners, Ascent
 Biomedical Ventures, Delphi Ventures and Frazier Heathcare Ventures.
 Additionally, Boston Scientific and Greatbatch, Inc. remain significant
 stockholders of InnerPulse.
     InnerPulse is pioneering a promising new technology that has the
 capacity to change how patients with cardiac rhythm disorders are treated.
 The Company's products employ an innovative technology to simplify the
 implant utilizing a minimally invasive approach that shortens the
 procedure, reduces post implant discomforts, and renders the device
 invisible. The minimally invasive nature of the technology will expand the
 number of implanting physicians, thereby providing access to more patients
 who critically need defibrillator technology.
     InnerPulse was founded in 2003 and has moved the development of the
 first product, the Percutaneous Implantable Cardioverter Defibrillator
 (PICD)(TM), through early development stage. Dan Pelak, President and CEO,
 commented: "We are very pleased with the quality of our investors and the
 level of financing we have achieved. InnerPulse has made significant
 progress to date and now has the resources to execute on our business plan
 with a focus towards the commercialization of our first generation product.
 This funding will allow our company the ability to commercialize a
 technology that will save the lives of many individuals with heart
     About InnerPulse, Inc
     Founded in 2003, InnerPulse is a privately held, early-stage company
 pioneering an alternative to traditional electrophysiological devices. More
 information is available at
     Contact:  Benny Ward, V.P. & C.F.O           Len Hall (media)
               InnerPulse, Inc                    Allen & Caron Inc
               919 287 4111                       949 474 4300

SOURCE InnerPulse, Inc

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.